{"id":46933,"date":"2022-08-04T14:01:42","date_gmt":"2022-08-04T12:01:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/tectraum-announces-american-medical-association-issuing-of-first-ever-category-iii-cpt-code-for-treating-concussions\/"},"modified":"2022-08-04T14:01:42","modified_gmt":"2022-08-04T12:01:42","slug":"tectraum-announces-american-medical-association-issuing-of-first-ever-category-iii-cpt-code-for-treating-concussions","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/tectraum-announces-american-medical-association-issuing-of-first-ever-category-iii-cpt-code-for-treating-concussions\/","title":{"rendered":"TecTraum Announces American Medical Association Issuing of First Ever Category III CPT Code for Treating Concussions"},"content":{"rendered":"
\n

\nCPT code for emerging technology represents important milestone for therapeutic assessment and treatment of sports-related concussions.\n<\/p>\n

CLEVELAND–(BUSINESS WIRE)–TecTraum Inc., dedicated to providing the world\u2019s first point-of-care treatment for concussions known as pro2cool\u00ae<\/sup><\/b>, announces today that the American Medical Association (AMA) has issued a new Category III Current Procedural Terminology (CPT\u00ae<\/sup>) code to help clinicians treat sports-related concussion symptoms with its flagship technology, pro2cool\u00ae<\/sup>. The AMA recognizes that healthcare technology evolves rapidly and developed Category III codes to recognize emerging technologies as a means of treating patients with noninvasive measures. CPT\u00ae<\/sup> is a registered trademark of the American Medical Association.\n<\/p>\n

<\/a><\/p>\n

\nThe pro2cool\u00ae<\/sup> system is a novel, noninvasive hypothermic therapy device designed to reduce the severity of concussion symptoms and allow patients to return to their pre-injury baseline sooner. The device provides localized cooling for the head and neck to lower blood temperature before it enters the brain. In previous clinical trials, researchers observed significant improvements in clinical outcomes through the cooling of the brain within days of the concussion.\n<\/p>\n

\nAccording to the U.S. Centers for Disease Control and Prevention (CDC), as many as 3.8 million sports and recreation-related concussions occur each year in the United States alone. Additionally, from 2001 to 2012, the rate of emergency room visits doubled for treating children with concussions. The AMA\u2019s website publishes updates of the CPT\u00ae<\/sup> Editorial Panel of the Category III codes in July and January, and they provide important clinical information. CPT\u00ae<\/sup> codes are used by Government payers and commercial health plans for reimbursement, but they also are intended to be used for data collection to validate more widespread usage or to provide documentation for the Food and Drug Administration (FDA) approval process.\n<\/p>\n

\n\u201cThis new recognition by the American Medical Association represents a major milestone for pro2cool\u00ae <\/sup>and captures the importance of the advancement and evolution of new technologies in the healthcare environment,\u201d said John Zak, MD, TecTraum\u2019s CEO. \u201cTecTraum is strongly positioned for revolutionizing the treatment of concussions and providing an essential medical device for young athletes. The Category III CPT\u00ae<\/sup> issuing brings us one step closer to delivering noninvasive concussion therapy to patients and will allow for important data collection needed to expand our usage beyond sports-related injuries.\u201d\n<\/p>\n

\nThe new Category III CPT\u00ae<\/sup> code for pro2cool\u00ae <\/sup>was awarded on July 1, 2022, however, is not able to be used in medical billing until TecTraum receives market authorization from the FDA. The new code that was awarded to the company (CPT 0776T) is defined as the following:\n<\/p>\n